CO2018014085A2 - Estabilización de formulaciones de ácido beta-hidroxiisovalérico en cápsulas de gel suave - Google Patents

Estabilización de formulaciones de ácido beta-hidroxiisovalérico en cápsulas de gel suave

Info

Publication number
CO2018014085A2
CO2018014085A2 CONC2018/0014085A CO2018014085A CO2018014085A2 CO 2018014085 A2 CO2018014085 A2 CO 2018014085A2 CO 2018014085 A CO2018014085 A CO 2018014085A CO 2018014085 A2 CO2018014085 A2 CO 2018014085A2
Authority
CO
Colombia
Prior art keywords
beta
soft gel
hydroxyisovaleric acid
stabilization
gel capsules
Prior art date
Application number
CONC2018/0014085A
Other languages
English (en)
Spanish (es)
Inventor
Martin Purpura
Ralf Jaeger
Jie Gu
Xiong Zheng
Yaohua Zhang
lingwei dai
Original Assignee
Tsi Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsi Group Ltd filed Critical Tsi Group Ltd
Publication of CO2018014085A2 publication Critical patent/CO2018014085A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CONC2018/0014085A 2016-05-25 2018-12-24 Estabilización de formulaciones de ácido beta-hidroxiisovalérico en cápsulas de gel suave CO2018014085A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662341464P 2016-05-25 2016-05-25
PCT/US2017/034551 WO2017205673A1 (en) 2016-05-25 2017-05-25 Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules

Publications (1)

Publication Number Publication Date
CO2018014085A2 true CO2018014085A2 (es) 2019-03-18

Family

ID=60411620

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0014085A CO2018014085A2 (es) 2016-05-25 2018-12-24 Estabilización de formulaciones de ácido beta-hidroxiisovalérico en cápsulas de gel suave

Country Status (12)

Country Link
US (3) US10959957B2 (enExample)
EP (1) EP3463327B1 (enExample)
JP (1) JP6929939B2 (enExample)
KR (1) KR102384266B1 (enExample)
CN (2) CN121177244A (enExample)
AU (1) AU2017270219B2 (enExample)
CA (1) CA3024584A1 (enExample)
CO (1) CO2018014085A2 (enExample)
MX (1) MX2018014407A (enExample)
MY (1) MY199597A (enExample)
RU (1) RU2018145520A (enExample)
WO (1) WO2017205673A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111888325A (zh) * 2020-08-04 2020-11-06 瑞希(重庆)生物科技有限公司 一种卡拉胶凝胶、药物赋形剂和皮肤外用制剂
JP7750505B2 (ja) * 2021-10-14 2025-10-07 中日本カプセル 株式会社 カプセル及びカプセルの製造方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870062A (en) * 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
US5200191A (en) 1991-09-11 1993-04-06 Banner Gelatin Products Corp. Softgel manufacturing process
US5569466A (en) 1995-05-17 1996-10-29 R. P. Scherer Corporation Fill compositions for soft elastic gel capsules
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
DE10064312C2 (de) 2000-12-22 2003-05-22 Degussa Cholinpyruvat-Hydrat, Verfahren zu dessen Herstellung, Cholinpyruvat-Hydrat enthaltende Formulierung sowie deren Verwendung
US7740878B2 (en) * 2001-10-22 2010-06-22 Danisco A/S Use of betaine to enhance exercise performance
ATE374602T1 (de) 2001-12-21 2007-10-15 Supernus Pharmaceuticals Inc Orale kapselformulierung mit verbesserter physikalischer stabilität
DE10208568A1 (de) 2002-02-27 2003-09-18 Degussa Bioactives Deutschland Verbindung, enthaltend Kreatin, eine Säure-Komponente und/oder einen Komplex-Bildner
DE10217557A1 (de) 2002-04-19 2003-11-06 Degussa Bioactives Gmbh Funktionsnahrungsmittel enthaltend eine Phospholipid-haltige stabile Matrix
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US8231896B2 (en) * 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
DE102004060914A1 (de) 2004-12-17 2006-07-06 Bioghurt Biogarde Gmbh & Co. Kg Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen
EP2242489A1 (en) * 2005-02-15 2010-10-27 Jallal Messadek Combination therapeutic compositions and method of use
DE102005061765A1 (de) 2005-05-19 2006-11-23 Degussa FreshTech Beverages LLC, Milwaukee Füllmaterial für einen Getränkebehälter
CN101574146B (zh) * 2008-05-07 2012-06-13 北京康比特体育科技股份有限公司 一种含有hmb的运动营养补剂
JP2009153529A (ja) * 2009-04-17 2009-07-16 Tsujido Chemical Corp 食品組成物
ES2608483T3 (es) * 2009-12-18 2017-04-11 Metabolic Technologies, Inc. Método mejorado de administración de beta-hidroxi-beta-metilbutirato (HMB)
CN103338658A (zh) 2010-12-22 2013-10-02 雅培制药有限公司 含有β-羟基-β甲基丁酸钙和共轭亚油酸的营养型产品
MX2014000419A (es) * 2011-07-15 2014-09-22 Nusirt Sciences Inc Composicones y metodos para modular trayectorias metabolicas.
BR112015005199B1 (pt) 2012-09-10 2022-09-06 Metabolic Technologies, Inc Composição, e, método para fornecer um benefício a um animal em necessidade do mesmo
BR112015010947A2 (en) 2012-11-13 2018-06-05 Nusirt Sciences, Inc. compositions and methods for increasing energy metabolism.
US20140272000A1 (en) 2013-03-14 2014-09-18 Metabolic Technologies, Inc. Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same
JP6389237B2 (ja) * 2013-03-15 2018-09-12 パセオン ソフトジェルズ インコーポレイティド 非ゼラチン性腸溶性軟質カプセル
HK1221609A1 (zh) 2013-05-01 2017-06-09 Abbott Laboratories 增强老化肌肉再生的方法
EP3082778B1 (en) * 2013-12-18 2019-04-03 Capsugel Belgium NV Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid
WO2015195990A1 (en) * 2014-06-20 2015-12-23 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
JP2018090504A (ja) * 2016-11-30 2018-06-14 株式会社東洋新薬 筋肉増強用組成物

Also Published As

Publication number Publication date
EP3463327B1 (en) 2024-04-17
JP2019517576A (ja) 2019-06-24
JP6929939B2 (ja) 2021-09-01
EP3463327A1 (en) 2019-04-10
US12133920B2 (en) 2024-11-05
RU2018145520A (ru) 2020-06-25
MX2018014407A (es) 2019-02-21
KR102384266B1 (ko) 2022-04-06
EP3463327A4 (en) 2020-01-22
AU2017270219A1 (en) 2018-11-29
AU2017270219B2 (en) 2023-03-16
US20170340572A1 (en) 2017-11-30
BR112018073949A2 (pt) 2019-02-26
EP3463327C0 (en) 2024-04-17
RU2018145520A3 (enExample) 2020-08-26
CA3024584A1 (en) 2017-11-30
US10959957B2 (en) 2021-03-30
US20250057773A1 (en) 2025-02-20
BR112018073949A8 (pt) 2023-03-21
US20210212953A1 (en) 2021-07-15
MY199597A (en) 2023-11-08
WO2017205673A1 (en) 2017-11-30
KR20190021259A (ko) 2019-03-05
CN121177244A (zh) 2025-12-23
CN109562087A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
CL2019000586A1 (es) Composiciones de toxinas clostridiales no proteicas.
WO2016042163A3 (en) Ophthalmic drug compositions
CL2019002810A1 (es) Compuestos inhibidores de ask1 y usos de los mismos.
CO2017012893A2 (es) Composiciones farmacéuticas que comprenden péptidos neo-antígenos o una sal de los mismos y métodos para preparar las mismas
UY37818A (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
BR112018003031A2 (pt) formulações clínicas
AR100519A1 (es) Envase tipo cápsula de gelatina blanda y su método de fabricación
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
MX2017010945A (es) Preparacion solida.
MX2018014631A (es) Formulacion de neurotoxina.
CL2016002607A1 (es) Procedimiento para preparar una preparación farmacéutica de acetato de glatiramer y manitol en un contenedor adecuado que comprende las etapas de obtener una solución acuosa de acetato de glatiramer y manitol, filtración de la solución entre 0 y 17,5 grado celsius y llenado del contenedor. pct
MX391152B (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
MX2018010395A (es) Formulaciones topicas que contienen cliclosporina y usos de las mismas.
AR105237A1 (es) Método y composiciones nutricionales que contienen fosfatidiletanolamina, esfingomielina y ácido docosahexaenoico
CL2018001151A1 (es) Suspensión acuosa para administración oral y método para su preparación
MX2019005160A (es) Formulacion farmaceutica.
PE20180928A1 (es) Sales y profarmacos de 1-metil-d-triptofano
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
CL2015002324A1 (es) Método para el tratamiento y control de enfermedades de postrecolección de frutas y hortalizas y composiciones que comprenden extractos naturales y formulaciones fitofortificantes y/o fungicidas para aplicar en dicho método.
MY199597A (en) Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules
CL2019003801A1 (es) Nuevas formulaciones orales de belinostato.
CL2018001797A1 (es) Formulación galénica que comprende un fármaco tópico
UY38043A (es) Combinación farmacéutica que comprende tramadol clorhidrato de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor
TR201815617A2 (tr) Deksketoprofen içeren bir formülasyon.
AR110319A1 (es) Composición para el tratamiento de la osteoartritis